Endpoints News – Alarmed that an imbalance in deaths among patients taking a combination of Keytruda with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint combos, the FDA has…
September 19, 2017
September 19, 2017
Honey can combat cancer, UAEU scientists find
Khaleej Times – Researchers at the United Arab Emirates University (UAEU) in Al Ain have made a groundbreaking discovery. They found out that tiny amounts of Manuka honey could prevent the growth of several types of cancer cells, including melanoma, breast adenocarcinoma and colorectal cancer.
The team has already filed a patent application in the US on their work. Their studies reflect…
September 19, 2017
CHIPSA Hospital Files Patent on Cancer Immunotherapy Combination of Checkpoint Inhibitors and Coley Vaccine
PR Web – CHIPSA Hospital, dedicated to the accelerated development of nontoxic cancer immunotherapies announced today filing of a patent application covering the combination of FDA approved antibodies known as “checkpoint inhibitors” together with Coley Vaccine, a stimulatory of innate immunity.
September 19, 2017
OncoSec Is Steadily Taking Its Place as a Leader in Immuno-Oncology
Equities.com – It’s rare to see microcap biotechnology companies rubbing elbows with majors in the space, but that’s exactly what’s going on with OncoSec Medical Inc. (ONCS). Wielding several FDA designations for its investigational technology, branded ImmunoPulse, for the treatment of cancer, OncoSec is collaborating with bigger peers like Merck (MRK) and Jounce Therapeutics (JNCE), well-capitalized drugmakers with interest in…
September 19, 2017
Keytruda Better than Standard Treatment for Advanced Head and Neck Cancer, Keynote-040 …
Immuno-Oncology News – Keytruda (pembrolizumab) may be more beneficial than standard therapy for patients whose head and neck cancer has spread or returned after a first round of chemotherapy.
That’s the conclusion of a Phase 3 study…